Background. For the evaluation and comparison of markers and risk prediction models, various novel measures have recently been introduced as alternatives to the commonly used difference in the area under the receiver operating characteristic (ROC) curve (DAUC). The net reclassification improvement (NRI) is increasingly popular to compare predictions with 1 or more risk thresholds, but decision-analytic approaches have also been proposed. Objective. We aimed to identify the mathematical relationships between novel performance measures for the situation that a single risk threshold T is used to classify patients as having the outcome or not. Methods. We considered the NRI and 3 utility-based measures that take misclassification costs into account: difference in net benefit (DNB), difference in relative utility (DRU), and weighted NRI (wNRI). We illustrate the behavior of these measures in 1938 women suspect of having ovarian cancer (prevalence 28%). Results. The 3 utility-based measures
Background. For the evaluation and comparison of markers and risk prediction models, various novel measures have recently been introduced as alternatives to the commonly used difference in the area under the receiver operating characteristic (ROC) curve (DAUC). The net reclassification improvement (NRI) is increasingly popular to compare predictions with 1 or more risk thresholds, but decision-analytic approaches have also been proposed. Objective. We aimed to identify the mathematical relationships between novel performance measures for the situation that a single risk threshold T is used to classify patients as having the outcome or not. Methods. We considered the NRI and 3 utility-based measures that take misclassification costs into account: difference in net benefit (DNB), difference in relative utility (DRU), and weighted NRI (wNRI). We illustrate the behavior of these measures in 1938 women suspect of having ovarian cancer (prevalence 28%). Results. The 3 utility-based measures appear to be transformations of each other and hence always lead to consistent conclusions. On the other hand, conclusions may differ when using the standard NRI, depending on the adopted risk threshold T, prevalence P, and the obtained differences in sensitivity and specificity of the 2 models that are compared. In the case study, adding the CA-125 tumor marker to a baseline set of covariates yielded a negative NRI yet a positive value for the utility-based measures. Conclusions. The decision-analytic measures are each appropriate to indicate the clinical usefulness of an added marker or compare prediction models since these measures each reflect misclassification costs. This is of practical importance as these measures may thus adjust conclusions based on purely statistical measures. A range of risk thresholds should be considered in applying these measures. Key words: clinical prediction rules; decision rules; decision analysis. (Med Decis Making 2013;33:490-501) R isk prediction models are essential tools in the era of personalized medicine. Such models provide estimates of diagnostic or prognostic outcomes that can support decision making in screening, diagnosis, and therapy choice across all medical fields. [1] [2] [3] Often competing models exist for the same outcome, for example, a model with or without a novel marker. Novel risk markers hold the promise to refine risk classification, which allows better targeting of individuals who will benefit from prevention or therapeutic interventions. 4 Another typical example of competing models is when different research groups have independently developed a prediction model.
The evaluation of risk prediction models, as well as the comparison of competing models, has traditionally focused on discrimination. Hereto, the area under the receiver operating characteristic (ROC) curve (AUC) is widely used. 5 This rank-order statistic assesses how well the model distinguishes between patients with and without the outcome of interest based on the estimated risks. More specifically, the AUC estimates the probability that a patient with the outcome is given a higher risk than a patient without the outcome. The incremental value of a new marker would then be assessed by the difference in AUCs (DAUC) for a model with the marker as a predictor variable and a model without. 6, 7 However, it is widely recognized that more advanced measures than AUC and DAUC are needed. [6] [7] [8] [9] [10] [11] The main issue is that the AUC lacks clinical interpretability. 11, 12 It is also unclear what value of DAUC is clinically important. Alternative measures have been suggested to evaluate the usefulness of a prediction model in practice-namely, assisting with clinical decisions regarding treatment. These include the net reclassification improvement (NRI), weighted NRI (wNRI), net benefit (NB), and relative utility (RU). [13] [14] [15] [16] [17] This article investigates the mathematical relationships between these measures. We hypothesize that many of the novel measures are closely related when a single decision threshold is considered. We illustrate the measures with a case study on ovarian tumor diagnosis.
METHODS

Terminology and Notation
We focus on prediction models for dichotomous outcomes. Extensions to survival-type data are possible 15, 17, 18 but beyond the scope of this article. The prediction model estimates the risk that the event is present in a given patient. A prediction rule is derived from the prediction model through a risk threshold T to classify patients as positive (presence of event) or negative. 19 Performance evaluation can focus on predictions or on classifications. 6, 19, 20 We assume a data set of size N, consisting of N 1 events and N -nonevents. The event prevalence (N 1 /N) is denoted as P. When using threshold T, we denote the number of true positives, false positives, true negatives, and false negatives by TP, FP, TN, and FN, respectively. The cost of each type of classification is denoted by c TP , c FP , c FN , and c TN .
If we have 2 prediction models, model 1 and model 2, subscripts are used to differentiate between results for the 2 models (e.g., TP 1 and TP 2 ). Given the dependence on T, the complete notation would be TP T , TP 1,T , and so on. However, for reasons of simplicity, we will omit the conditioning on T in the notation.
Classification as a Decision Problem
For patient classification, we could aim for a threshold that simultaneously optimizes classification of events and nonevents. 20 However, this strategy does not take misclassification costs into account. 21 Disease seriousness, as well as treatment consequences of patient classification, implies that the benefit of accurately classifying diseased patients is often quite different from the harm of assuming disease in nondiseased patients. Usually, benefit of treating a diseased patient exceeds the harm of overtreatment. 19 The issue, then, is the choice of a risk threshold that takes the harm-to-benefit ratio into account. The risk threshold can be defined as the risk of the outcome at which one is indifferent about treatment or no treatment, since the expected utility/ cost is equal. 22 It is well known that there is a direct relationship between the risk threshold and the harm-to-benefit ratio. 13, 23 If we predict absence of disease in a patient with a risk of disease that equals the threshold T, the expected cost will be
If we predict presence of disease, the expected cost will be
One is indifferent about treatment if both expected costs are equal. Working out this equality gives
Now, c TN -c FP is the benefit of not treating a nondiseased patient or, equivalently, the harm of a false positive. Likewise, c TP -c FN is the benefit of providing treatment to diseased patients or, equivalently, the benefit of a true positive. The risk threshold directly informs us about the harm-to-benefit ratio. More specifically,
Thus, the odds of T equal the ratio of harm to benefit. This equality was already documented by Pauker and Kassirer 22 and by many researchers thereafter. 13, [15] [16] [17] [24] [25] [26] For example, adopting a threshold of 0.05 indicates that a true positive is 19 times more important than a false positive or that a falsenegative classification is 19 times more costly than a false-positive classification. When a threshold of 0.5 is used, both types of misclassifications are considered equally harmful.
Classification based on T can be done using the estimated risks from a prediction model, but these risks need to be calibrated to correspond to the intended harm-to-benefit ratio. Calibration means that predicted risks agree with observed outcomes. However, the mathematical relationships between the measures presented in this article hold irrespective of calibration.
The preferred value of T typically varies between individuals. Therefore, as a sensitivity analysis, the performance of prediction rules should be reported for different values of T.
13,17
Case Study: Ovarian Tumor Diagnosis
It is important to accurately characterize an ovarian tumor as benign or malignant prior to surgery. Appropriate treatment of malignant tumors by specialized gynecological oncologists improves prognosis, whereas misdiagnosis of malignancy incurs unnecessary intervention levels. The International Ovarian Tumor Analysis (IOTA) consortium has developed a risk prediction model based on 6 demographic and ultrasound-based variables to assist clinicians in assessing the risk of malignancy. 27 The model does not contain the CA-125 tumor marker, and there is ongoing debate concerning its role in diagnosing ovarian tumors. Therefore, we compare the IOTA model with an extended model that also includes CA-125. The models were developed on data from 1066 patients collected at 9 centers between 1999 and 2002, with a 25% prevalence of malignancy. We validated the models on 1938 patients collected at 19 centers between 2005 and 2007, with a prevalence of 28%. 28 For each patient, the estimated risk of malignancy was obtained from the linear predictor, which was computed by multiplying the estimated regression coefficients with the patients' covariate values. Figure 1a shows ROC curves for the models.
False negatives are extremely harmful because patients would not receive appropriate surgery (e.g., laparotomy, interval-debulking) that has proved to strongly determine survival of patients. False positives should be avoided to save costs and unnecessary examinations and extensive surgery, but they are less harmful. The risk threshold (T) adopted by most clinicians and patients will be 10% or lower. We illustrate calculations for T = 5%, with interest in thresholds between 2% and 10%. In the absence of risk prediction, the default strategy would be to consider all patients as having ovarian cancer and treat them accordingly.
Performance Measures
The evaluation of model predictions involves a summary of performance over all possible thresholds. To this end, AUC and DAUC are traditional measures. When evaluating model classifications, the Youden index is common. 29 Recently, NRI has been suggested to compare classifications obtained by 2 models.
14 For a single risk threshold T, NRI equals the difference in the Youden index (DYouden). 14, 15 The Youden index assigns the same importance to the performance for events and nonevents and does not account for differential consequences of classifications. It has been labeled a measure of the success or ''science of the method'' by Peirce. 30 In contrast, decision-analytic measures have been proposed that do consider these differential consequences, for example, NB (and the difference DNB when comparing 2 models), RU (DRU), and wNRI. In Peirce's terminology, these measures consider the ''utility of the method'' (Table 1) .
Net Reclassification Improvement
NRI quantifies the improvement in the reclassification of cases into risk groups when 2 competing models are compared using the same risk threshold(s).
14 Events should be reclassified to higher risk groups (''up'' in equation (5)); nonevents should move in the opposite direction (''down''). For events and nonevents separately, the proportion of cases reclassified in the correct direction minus the proportion of cases reclassified in the incorrect direction is computed to obtain the event NRI and nonevent NRI. The NRI can then be written as
The NRI can be used for 2 risk groups based on 1 risk threshold but also for 3 or more risk groups based VAN CALSTER AND OTHERS Evaluation of predictions (summary measures over all possible thresholds) DAUC Equal to difference in Mann-Whitney statistics; rank-order statistic Evaluation of classifications (using a risk threshold to define 2 groups) ''Science of the method'' NRI T Sum of differences in sensitivity and specificity; identical to DYouden ''Utility of the method'' DNB T (TP -wFP)/N DRU T Expresses NB T relative to the net benefit of the baseline strategies and the maximum net benefit wNRI T Weights the NRI T with misclassification costs on 2 or more thresholds. We use the notation NRI T as we focus on the NRI for 2 risk groups using T. 15 We can reformulate NRI T as follows:
NRI T is the sum of improvement in sensitivity (event NRI T ) and specificity (nonevent NRI T ). For appropriate interpretability, event NRI T and nonevent NRI T should be reported as well. 14, 15 By dividing the difference in true positives by N 1 and the difference in false positives by N -, NRI T eliminates the influence of prevalence such that sensitivity and specificity are considered equally important. NRI T does not account for harms, and hence it has the following ambiguity: TP and FP are a consequence of the chosen threshold T, which reflects the harm-to-benefit ratio, but this ratio is not explicitly used to quantify performance. A weighted version of NRI T has therefore been proposed, 15 as discussed later.
As NRI T equals DYouden, Figure 1b shows the Youden index of the ovarian tumor models by varying T.
Net Benefit
The NB, written as NB T to be consistent in notation, corrects TP for FP based on misclassification costs 13, 31 and is written as
The benefit of a true positive is considered equivalent to the harm of w false positives. The weight w for false positives is defined as odds(T), or the harm-tobenefit ratio that corresponds to threshold T. 13 By penalizing TP for wFP, NB is the net proportion of true-positive classifications. NB T can be plotted as a function of T, yielding a decision curve. Figure 1c shows the decision curves for the ovarian tumor models.
A model can be compared with 2 baseline strategies: ''treat none'' (i.e., always predict absence of disease) and ''treat all'' (i.e., always predict disease). NB treat none is always zero as there are no true or false positives. For treat all,
NB T can be interpreted as the equivalent of the increase in the proportion of true positives relative to ''treat none,'' without an increase in false positives. Alternatively, the improvement over NB treat all when divided by w, (NB T -NB treat all )/w, is the equivalent of the decrease in the proportion of false positives relative to ''treat all,'' without a decrease in true positives. Decision curve analysis is an elegant way of evaluating the clinical consequences of classifications derived from a prediction model without performing a formal and complex decision analysis. 13, 31 The difference in NB T (DNB T ) of model 1 and model 2 is given as follows:
DNB T can be interpreted as being equivalent to the increase in the proportion of true positives without a change in false positives when using model 2 instead of model 1. Alternatively, DNB T /w is the equivalent of the decrease in the proportion of false positives without a decrease in true positives.
Relative Utility RU T is the net benefit in excess of ''treat all'' or ''treat none'' (whichever is larger) divided by the net benefit of perfect prediction. RU T focuses on ''treat all'' if T \ P (or, equivalently, if treatment is given in the absence of prediction) and on ''treat none'' if T ! P (or, equivalently, if no treatment is given in the absence of prediction). RU T and NB T are based on the theory of expected utility, and their detailed description within this framework can be found elsewhere. 17, 32 RU T expresses the utility of a model as the proportion of the maximal gain relative to the best baseline strategy at risk threshold T. RU T can be plotted as a function of T in a relative utility curve, as illustrated in Figure 1d for the ovarian tumor models. The difference in RU T (DRU T ) of model 1 and model 2 is defined in an analogous manner as for NB T .
Weighted Net Reclassification Improvement
The critique that NRI does not take cost considerations into account 21, 33 led to the introduction of the weighted NRI (wNRI T when focusing on 2 risk groups based on T). 15 The savings or benefit when an event is reclassified to a higher risk group by model 2 than by model 1 is denoted by s 1 . Likewise, s 2 is used to denote the benefit obtained when a nonevent is reclassified to a lower risk group by model 2. When using Bayes' rule on the NRI and including s 1 and s 2 , wNRI equals
The ratio of s 2 and s 1 , for a prediction rule with 2 risk groups, corresponds to a harm-to-benefit ratio and was defined as odds(T) to be consistent with the adopted threshold. 15 If we set s 1 = 1/P and s 2 = 1/(1 -P), we would obtain the original NRI T . For wNRI T , s 1 and s 2 are chosen to maintain the harmonic mean of the original weights 1/P and 1/(1 -P), 15 which is 2. By consequence, s 1 = 1/T and s 2 = 1/(1 -T).
Overview of Relationships between Performance Measures
An overview of relationships between measures to quantify performance for dichotomous classifications is presented in Table 2 . More details on the derivation of these relationships are given in the Appendix. The main finding is that the utility-based measures DNB T , DRU T , and wNRI T are transformations of one another and thus lead to consistent conclusions.
After simple rearrangements of terms, NRI T , DNB T , DRU T , and wNRI T are measures with a very similar setup:
Alternatively, these measures can be expressed as a weighted sum of the differences in sensitivity and specificity (DSe and DSp):
The decision-analytic measures account for disease prevalence and the harm-to-benefit ratio and are thus consistent approaches that are simple transformations of one another. They differ in the specific weights used for DTP and DFP (or DSe and DSp). NB T uses weights to obtain a result that can be expressed in basic clinical terms relating to the net number of true positives per 1000 patients. RU uses weights depending on whether or not T\ P, to express NB T relative to the appropriate baseline strategy and to perfect classification. If T\P, NB T is compared with ''treat all'' (specificity 0%). Equation (11) shows that RU T,T\P corrects the true-negative rate for the cost-adjusted number of false negatives divided by 1 -P, such that the result is expressed on the scale of specificity. Likewise, if T ! P, NB T is compared with ''treat none'' (sensitivity 0%), and RU T,T!P corrects the true-positive rate for the cost-adjusted number of false positives divided by P to obtain a result on the scale of sensitivity. Finally, wNRI T differs from NB T through the choice of s 1 and s 2 based on a desired harmonic mean of 2.
Maximum Test Harm of the New Marker
When evaluating the added value of a marker, DNB T , DRU T , and wNRI T inform on the maximum test harm of the new marker. If the test harm of the marker exceeds its added utility, the model without 
of T and P NRI T = DYouden NRI T = 2*DAUC T (i.e., twice the difference in the areas under the prediction rules' single-point receiver operating characteristic curves)
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the new marker may still be preferred. Test harm can be quantified through the test tradeoff 32 that is computed as 1/DNB T . The test tradeoff is the minimum required number of patients tested with the new marker (as part of the extended model) per extra true positive, in order for the increase in net benefit corrected for test harm to be greater than zero. The test tradeoff is weighted against the harm associated with obtaining the value of the new marker. For example, a test tradeoff might be acceptable with a test for a new marker that is not invasive but not acceptable with an invasive test. In other words, if the test tradeoff is too high, the added utility of the new marker does not compensate the harm associated with obtaining the marker value.
When Are NRI T and Decision-Analytic Measures Inconsistent?
NRI T and decision-analytic measures can have an opposite sign only when the classification of one outcome improves and the classification of the other outcome deteriorates (i.e., when DTP and DFPhave the same sign). Furthermore, DNB T is 0 when DTP 5 wDFP, whereas NRI T is 0 when DTP 5 P 1ÀP DFP. It follows that, when DTP and DFP are both positive, DNB T is positive and NRI T negative when
and the reverse is observed when
When DTP and DFP are both negative, the inequality signs should be switched. This indicates that a large difference between (the odds of) T and P enhances the possibility of contradiction.
Next to the issue of opposite signs, it is also important to discuss inconsistency in strength, that is, when decision-analytic measures will be strongly supportive of model 2 in case NRI T is modest or vice versa. We assume the situation that we have computed DSe and DSp as well as NRI T and that DSe and DSp are positive. If at this point a decisionanalytic evaluation is desired, P and T come into play. Given DSe and DSp, equation (12) indicates that the effect of P on DNB T depends on the value of w, more specifically whether or not w . DSe/DSp. The effect of T is clearer: Given DSe and DSp, DNB T is higher when the adopted T for classification is higher. Then, if NRI T is supportive of model 2, DNB T can be disappointing if w is low and P is either low (if w \ DSe/DSp) or high (if w . DSe/DSp). Let us demonstrate with an example. Assume that DSe = DSp = 0.05 (both increased with 5 percentage points), such that NRI T = 0.1. If T was set at 5% and P is 10%, the associated DNB T is 0.007, suggesting 7 additional true positives per 1000 patients at the same level of false positives. However, if T was set at 20%, the DNB T increases to 0.016. With T at 5% but P at 50% instead of 10%, DNB T even rises to 0.026.
Calibration
The level of calibration affects performance of a prediction rule. With overprediction (estimated risks are too high), the true cutoff is smaller than T, leading to more true and false positives than intended. The opposite, underprediction, is typically worse because some patients would not get the intended treatment. When comparing models, miscalibration of one or both models causes the actually used cutoffs to differ such that models are not compared on equal grounds. Calibration performance is affected by the model and the population to which the model is applied. Therefore, it can be argued that its possibly negative effects on decision-analytic measures should play their role. On the other hand, it can also be useful to recalibrate a model to assess whether it changes conclusions. Nevertheless, calibration has no effect on the mathematical relationships between measures. Once T is specified, it is used by both models to classify patients and leads to fixed quantities TP 1 , TP 2 , FP 1 , and FP 2 .
RESULTS FOR THE CASE STUDY
Given the skewed distribution of CA-125, the marker was log 2 -transformed when adding it to the extended model. The odds ratio was 1.47 (95% confidence interval [CI], 1.26-1.72), indicating that the odds of malignancy increased by 47% per doubling of CA-125. The AUC increased by 0.008 (95% CI, 0.004-0.013) from 0.934 to 0.942 (Table 3 ). This difference cannot be interpreted in a meaningful way, but many investigators would consider this a limited improvement. The NRI 0.05 equaled 20.010 (95% CI, 20.033 to 0.011): The sum of the differences in sensitivity and specificity decreased with 1.0 percentage points. The sensitivity improved with 1.1 percentage points, but the specificity deteriorated with 2.1 percentage points. The DNB 0.05 was 0.0023 (95% CI, 20.0011 to 0.0064). This difference can be interpreted as equivalent to an additional 2.3 detected cancers per 1000 patients without an increase in unnecessary invasive surgeries or, equivalently, to a decrease in 44 unnecessary invasive surgeries per 1000 patients at the same level of detected cancers (DNB 0.05 /w = 0.0437). Contrary to NRI 0.05 , DNB 0.05 suggested that the CA-125 marker has added value, although the confidence intervals reveal substantial uncertainty in the point estimates. wNRI 0.05 is proportional to DNB 0.05 , so a transformation is needed to obtain the same interpretation. The difference in relative utility was 0.061 (-0.029% to 0.165%), indicating a 6.1 percentage point increase in the percentage improvement over ''treat all.'' Or, as T \ P, this indicates the increase in net specificity obtained by model 2: At the same level of sensitivity, model 2's specificity is 6.1 percentage points higher. The test tradeoff derived from the decision-analytic measures was 435. This means that per true positive at least 435 patients need to have CA-125 tested to make risk prediction with model 2 worthwhile. Figure 2 demonstrates that the decision-analytic measures always give concordant recommendations but that NRI T may give a different recommendation. These curves show that the CA-125 marker mainly has value when T ! 0.60. This observation explains why summary measures over all possible thresholds point at an advantage of adding the CA-125 marker. However, high-risk thresholds are irrational in this example as it would lead to an unacceptable number of women with cancer who would be denied appropriate treatment.
The calibration plots for both models are shown in Figure 3 . After calibration using local regression (loess) as in the calibration plots, sensitivity increased with 0.2 percentage points and specificity with 2.4 percentage points. Then, NRI 0.05 equaled 0.026, DNB 0.05 equaled 0.0014, and DRU 0.05 equaled 0.038. NRI 0.05 became more supportive of model 2, whereas decision-analytic measures became less supportive, but now they go in the same direction. The test tradeoff was 695 tested patients per extra true positive.
There is publicly available software for net benefit and decision curve analysis (www.decisioncurveanalysis.org; www.clinicalpredictionmodels.org). A simple approach for evaluating a new marker based on relative utility curves and test tradeoff (which is easily extended to survival data and the computation of confidence intervals) is based on calculations involving risk stratification tables. 16, 32 The risk threshold T is set at 0.05. CI, confidence interval. a Approximate confidence intervals were obtained using the bias-corrected bootstrap method based on 1000 replicates of the data set. Figure 2 Curves showing NRI T , DNB T , DRU T , and wNRI T (full, dashed, dotted, and dash-dotted lines, respectively) when varying the risk threshold on the x-axis. Vertical lines indicate the risk threshold T of 5% and the prevalence P of 28%.
DISCUSSION
In this article, we described the mathematical relationships between novel threshold-based measures to evaluate and compare markers and prediction models. The main result is that 3 recently suggested measures that incorporate misclassification costs-DNB T , 13 DRU T , 17 and wNRI T 15 -are transformations of each other and hence always lead to consistent conclusions. On the other hand, these conclusions may change when shifting to measures that do not weight binary classifications by misclassification costs such as with NRI T . To what extent conclusions differ depends on DSe and DSp, the adopted risk threshold T and prevalence. Further simulations would be needed to elucidate how common such differences are and what magnitude they may reach.
Following decision theory, we argue that DNB T , DRU T , or wNRI T be used when classifications obtained by competing models are compared. The adopted T conveys information on the assumed relative misclassification costs. Consequently, when classifications are evaluated without correction for misclassification costs, implicitly assumed information is ignored. To be consistent with decision theory, it is essential that the correction for misclassification costs uses the harm-to-benefit ratio assumed by T. Such consistency between classifications and their evaluations is present in NB T , RU T , and wNRI T . To account for variability concerning the preferred risk threshold, T needs to be varied as a sensitivity analysis.
With respect to interpretation, DNB T , DRU T , and wNRI T are different. DNB T can be interpreted in basic clinical terms as the change in the proportion of true positives at the same level of false positives or, if divided by w, as the change in false positives at the same level of true positives. Even though wNRI T equals DNB T /T, its interpretation is less straightforward in clinical terms despite its statistical interpretation. RU T can be considered as a rescaling of the NB T relative to the best default strategy and to perfect classification, and thus it represents the proportion of the possible improvement over the default strategy that is captured by the model. RU T can be more specifically interpreted as the net specificity (if T \ P) or net sensitivity (if T ! P). Then, DRU T reflects the change in specificity at the same level of sensitivity or as the change in sensitivity at the same level of specificity. Therefore, from a decision-analytic perspective, DRU T needs to be interpreted together with the prevalence. For example, DRU T of 0.1 with T = 0.2 has a quite different meaning when prevalence is 1% (DNB T = 0.0010; 10 more net true positives per 10,000) or 30% (175 more net true positives per 10,000). However it can be useful to understand the separate contributions of both prevalence and relative utility, as when computing the test tradeoff.
An important aspect of prediction models is the extent to which estimated risks are calibrated (i.e., correspond to observed outcomes). systematic differences between predicted risks and observed outcomes are often found. 2 If the model is not well calibrated, some patients will not be managed as intended. Such miscalibration also affects model performance using decision-analytic measures as w becomes inconsistent with TP and FP. This may be seen as problematic, but calibration performance is an inherent part of a prediction model. Miscalibration does not invalidate the mathematical relationships between the measures as described in this work.
A limitation of this work is the focus on classification into 2 groups. Sometimes more risk groups are desired. We may, for example, classify patients into low-, intermediate-, and high-risk groups, with further testing in the intermediate-risk group. 32 Alternatively, each risk group may be associated with a different treatment. A well-known example of such 3-group classification is in the prevention of cardiovascular disease, with different medical management strategies suggested for different risk categories.
14 A strength of the NRI is that it works with any number of risk groups. Research is needed on the extension of decision-analytic measures to situations with 3 or more risk groups, each with different treatments. Furthermore, the empirical behavior of reclassification measures and decision-analytic measures needs further study, as an extension to the relationships discussed here.
In conclusion, application of prediction models in a decision-making context implies use of a specific risk threshold. Then, DNB T , DRU T , and wNRI T are appropriate measures to indicate clinical usefulness. These novel measures are simple transformations of each other, thus leading to identical conclusions. We recommend using the decision-analytic measures for a range of sensible risk thresholds.
APPENDIX: DERIVATION OF RELATIONSHIPS Net Benefit and Relative Utility
If T \ P, RU T can be expressed as
If T ! P, RU T can be expressed as RU T;T ! P 5 NB T À NB treat none NB max À NB treat none
Thus, if T ! P, RU T equals NB T divided by P. If T \ P, the relationship is slightly more complex. These results lead to the following relationships with DNB T :
Net Reclassification Improvement NRI T can be expressed as
This formula is very similar to DNB T . The main difference is that P instead of T is used to weight the false positives. Thus, if T = P, a special situation occurs when the threshold T equals P, because this makes the NRI T mathematically proportional to DNB T and identical to DRU T ,
Also, if T ! P, the NRI T equals the difference in RU T for both models with a prevalence-based weight (i.e., odds of P, P/(1 -P)) rather than threshold-based weight (w) for the difference in false positives FP 2 -FP 1 .
There is a relationship between NRI T and ROC curves. The area under the prediction rule's singlepoint ROC curve, AUC T , is the average of sensitivity and specificity. Hence, NRI T equals twice the difference of AUC T for both models, NRI T = 2*(DAUC T ). 10 Links between the Youden index and AUC T have been reported earlier. 34 
Weighted Net Reclassification Improvement
Let n event,ij denote the number of events classified as i = 0,1 by model 1 and j = 0,1 by model 2. Furthermore, n non-event,ij is defined analogously. wNRI T can then be rewritten as wNRI T 
Thus, wNRI T is a scaled version of DNB T between the 2 models. Given that s 1 = 1/T, the relationship between wNRI T and DNB T is
Furthermore, if T ! P, it follows from previous relationships that wNRI T 
Finally, if T = P,
Similar to DNB T and DRU T , wNRI T can be plotted as a curve by varying the risk threshold T.
